NCT06571864View on ClinicalTrials.gov

AL Amyloidosis and Anti-CD38-Daratunumab

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 2, 2022

Primary Completion Date

January 2, 2024

Study Completion Date

February 2, 2024

Conditions
Amyloidosis
Interventions
DRUG

Anti-CD38 Monoclonal Antibody

Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)

Trial Locations (1)

10154

San Giovanni Bosco Hospital, Turin

All Listed Sponsors
lead

University of Turin, Italy

OTHER

NCT06571864 - AL Amyloidosis and Anti-CD38-Daratunumab | Biotech Hunter | Biotech Hunter